Table 4.
Baseline | Follow-up | p value | |
---|---|---|---|
sRANKL (pmol/L) | 0.32 [0.21–0.67] | 0.18 [0.11–0.35] | 0.0085∗∗ |
OPG (pmol/L) | 4.34 [2.60–5.82] | 4.22 [3.05–5.08] | 0.7990 |
sRANKL/OPG | 0.08 [0.04–0.17] | 0.05 [0.03–0.07] | 0.0031∗∗,† |
DKK1 (pmol/L) | 25.5 [18.1–43.3] | 26.4 [21.9–31.7] | 1.000 |
Sclerostin (pmol/L) | 25.2 [16.94–33.8] | 25.2 [19.2–29.3] | 0.8577 |
CTX-I (ng/mL) | 194.6 [176.6–430.7] | 163.6 [152.1–173.9] | 0.0005∗∗∗,† |
P1NP (ng/mL) | 55.7 [46.3–61.3] | 45.8 [39.6–48.9] | 0.0252∗ |
CTX/P1NP | 3.36 [3.09–3.82] | 3.71 [3.34–4.30] | 0.5590 |
Enzyme-linked immunosorbent assay results are shown as median and interquartile range. sRANKL: soluble receptor activator of NF-κβ ligand; OPG: osteoprotegerin; DKK1: Dickkopf-related protein-1: CTX: carboxyterminal telopeptide of type I collagen; P1NP: total procollagen type 1 N-terminal propeptide; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. †Remained significant after correction for multiple comparisons.